Precision pen on Lab White
ZENLUMA
GHK-Cu copper peptide
A copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to copper), synthesized to a written specification and verified at the molecular level before listing. One of the most extensively studied peptides in skin and connective-tissue research.
Ships FREE from within Canada · No customs · no border delays.
OVERVIEW
A copper tripeptide with a long record in skin research.
ZENLUMA is built on GHK-Cu, a copper-binding tripeptide first isolated from human plasma in 1973. It has been studied for decades in the context of skin remodelling, extracellular-matrix biology and wound research, making it one of the most thoroughly characterised peptides in the dermatological literature. Research interest centres on the peptide's affinity for copper and its observed activity in connective-tissue and matrix studies. ZENLUMA is a research-grade formulation, not an authorized medicine, and Zenovate makes no claim about cosmetic or therapeutic effects in humans. Every ZENLUMA batch is synthesized to a written specification and verified at [purity]% purity by an independent accredited Canadian laboratory, with the full certificate published before the batch is ever listed.
SPECIFICATIONS
THE RESEARCH
Cited research areas: GHK-Cu in skin and matrix remodelling; collagen-gene expression and angiogenic signalling; peptide stability and formulation chemistry.
We cite the literature. We make no claims about effects or outcomes, and no comparison to prescription products.
Identity · purity · stability
TESTING & QUALITY ASSURANCE
Every batch is tested before it ships.
COMPOUND FAQ
Questions specific to ZENLUMA.
Is ZENLUMA a prescription medicine?
No. ZENLUMA is a research-grade formulation with no marketing authorization in Canada; it is not a medicine and not a substitute for one.
How do I verify what is in a ZENLUMA vial?
Every batch is tested for identity, purity and stability by an independent accredited laboratory using UPLC / HPLC, LC-MS and related methods. Our full testing methodology is published on the Lab Results page.
Why does Zenovate avoid naming prescription brands?
Because comparing a research compound to an authorized medicine would be both misleading and non-compliant; they are different categories held to different standards of evidence.
Compounded products are not evaluated by Health Canada for safety, effectiveness or quality. ZENLUMA is a research-grade formulation, not a medicine, and nothing on this page is medical advice. For adults 19 and older.